BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Bleomycin
,
rs4950928
,
IL1A
,
glucose metabolic process
,
Arthritis
,
Liver
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
acid niflumic
Summary
General Info
Curated Studies
Most Correlated Studies
Broad Connectivity Map (CMAP 2.0) compound database
Explore Curated Studies Results
Literature
Most Relevant Literature
Analysis of submicron-sized niflumic acid crystals prepared by electrospray crystallization.
Niflumic acid inhibits goblet cell degranulation in a Guinea pig asthma model.
Contribution of pH to systemic exposure of niflumic acid following oral administration of talnifluma…
Urinary toxicological screening: analytical interference between niflumic acid and cannabis].
Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosy…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Bioavailability Study of Psilocybin in Normal Adults
Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal o…
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal…
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ